1 Angiotensin Converting Enzyme (ACE) Inhibitors Market Overview 1.1 Product Overview and Scope of Angiotensin Converting Enzyme (ACE) Inhibitors 1.2 Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Type 1.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth Rate Comparison by Type (2021-2027) 1.2.2 Sulfhydryl-containing Agents 1.2.3 Dicarboxylate-containing Agents 1.2.4 Phosphonate-containing Agents 1.3 Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Application 1.3.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Comparison by Application: (2021-2027) 1.3.2 Hypertension 1.3.3 Cardiovascular Diseases 1.3.4 Kidney Diseases 1.3.5 Other 1.4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size Estimates and Forecasts 1.4.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue 2016-2027 1.4.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales 2016-2027 1.4.3 Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Region: 2016 Versus 2021 Versus 2027 2 Angiotensin Converting Enzyme (ACE) Inhibitors Market Competition by Manufacturers 2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Manufacturers (2016-2021) 2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Manufacturers (2016-2021) 2.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Average Price by Manufacturers (2016-2021) 2.4 Manufacturers Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Sites, Area Served, Product Type 2.5 Angiotensin Converting Enzyme (ACE) Inhibitors Market Competitive Situation and Trends 2.5.1 Angiotensin Converting Enzyme (ACE) Inhibitors Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Angiotensin Converting Enzyme (ACE) Inhibitors Players Market Share by Revenue 2.5.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Angiotensin Converting Enzyme (ACE) Inhibitors Retrospective Market Scenario by Region 3.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Retrospective Market Scenario in Sales by Region: 2016-2021 3.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Retrospective Market Scenario in Revenue by Region: 2016-2021 3.3 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Facts & Figures by Country 3.3.1 North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country 3.3.2 North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Facts & Figures by Country 3.4.1 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country 3.4.2 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Facts & Figures by Region 3.5.1 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region 3.5.2 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market Facts & Figures by Country 3.6.1 Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country 3.6.2 Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Facts & Figures by Country 3.7.1 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country 3.7.2 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Historic Market Analysis by Type 4.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2016-2021) 4.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type (2016-2021) 4.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Price by Type (2016-2021) 5 Global Angiotensin Converting Enzyme (ACE) Inhibitors Historic Market Analysis by Application 5.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2016-2021) 5.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Application (2016-2021) 5.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Price by Application (2016-2021) 6 Key Companies Profiled 6.1 Abbott Laboratories 6.1.1 Abbott Laboratories Corporation Information 6.1.2 Abbott Laboratories Description and Business Overview 6.1.3 Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.1.4 Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio 6.1.5 Abbott Laboratories Recent Developments/Updates 6.2 Pfizer 6.2.1 Pfizer Corporation Information 6.2.2 Pfizer Description and Business Overview 6.2.3 Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.2.4 Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio 6.2.5 Pfizer Recent Developments/Updates 6.3 Novartis 6.3.1 Novartis Corporation Information 6.3.2 Novartis Description and Business Overview 6.3.3 Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.3.4 Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio 6.3.5 Novartis Recent Developments/Updates 6.4 Merck 6.4.1 Merck Corporation Information 6.4.2 Merck Description and Business Overview 6.4.3 Merck Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Merck Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio 6.4.5 Merck Recent Developments/Updates 6.5 Astra Zeneca 6.5.1 Astra Zeneca Corporation Information 6.5.2 Astra Zeneca Description and Business Overview 6.5.3 Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.5.4 Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio 6.5.5 Astra Zeneca Recent Developments/Updates 6.6 Jhonson and Johnson 6.6.1 Jhonson and Johnson Corporation Information 6.6.2 Jhonson and Johnson Description and Business Overview 6.6.3 Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.6.4 Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio 6.6.5 Jhonson and Johnson Recent Developments/Updates 6.7 Eli Lilly 6.6.1 Eli Lilly Corporation Information 6.6.2 Eli Lilly Description and Business Overview 6.6.3 Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio 6.7.5 Eli Lilly Recent Developments/Updates 6.8 Sanofi 6.8.1 Sanofi Corporation Information 6.8.2 Sanofi Description and Business Overview 6.8.3 Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.8.4 Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio 6.8.5 Sanofi Recent Developments/Updates 6.9 Bristol-Myers Squibb 6.9.1 Bristol-Myers Squibb Corporation Information 6.9.2 Bristol-Myers Squibb Description and Business Overview 6.9.3 Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.9.4 Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio 6.9.5 Bristol-Myers Squibb Recent Developments/Updates 6.10 Bayer 6.10.1 Bayer Corporation Information 6.10.2 Bayer Description and Business Overview 6.10.3 Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.10.4 Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio 6.10.5 Bayer Recent Developments/Updates 6.11 GSK 6.11.1 GSK Corporation Information 6.11.2 GSK Angiotensin Converting Enzyme (ACE) Inhibitors Description and Business Overview 6.11.3 GSK Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.11.4 GSK Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio 6.11.5 GSK Recent Developments/Updates 6.12 Teva Pharmaceutical 6.12.1 Teva Pharmaceutical Corporation Information 6.12.2 Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Description and Business Overview 6.12.3 Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.12.4 Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolio 6.12.5 Teva Pharmaceutical Recent Developments/Updates 7 Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Cost Analysis 7.1 Angiotensin Converting Enzyme (ACE) Inhibitors Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Angiotensin Converting Enzyme (ACE) Inhibitors 7.4 Angiotensin Converting Enzyme (ACE) Inhibitors Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Angiotensin Converting Enzyme (ACE) Inhibitors Distributors List 8.3 Angiotensin Converting Enzyme (ACE) Inhibitors Customers 9 Angiotensin Converting Enzyme (ACE) Inhibitors Market Dynamics 9.1 Angiotensin Converting Enzyme (ACE) Inhibitors Industry Trends 9.2 Angiotensin Converting Enzyme (ACE) Inhibitors Growth Drivers 9.3 Angiotensin Converting Enzyme (ACE) Inhibitors Market Challenges 9.4 Angiotensin Converting Enzyme (ACE) Inhibitors Market Restraints 10 Global Market Forecast 10.1 Angiotensin Converting Enzyme (ACE) Inhibitors Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Angiotensin Converting Enzyme (ACE) Inhibitors by Type (2022-2027) 10.1.2 Global Forecasted Revenue of Angiotensin Converting Enzyme (ACE) Inhibitors by Type (2022-2027) 10.2 Angiotensin Converting Enzyme (ACE) Inhibitors Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Angiotensin Converting Enzyme (ACE) Inhibitors by Application (2022-2027) 10.2.2 Global Forecasted Revenue of Angiotensin Converting Enzyme (ACE) Inhibitors by Application (2022-2027) 10.3 Angiotensin Converting Enzyme (ACE) Inhibitors Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Angiotensin Converting Enzyme (ACE) Inhibitors by Region (2022-2027) 10.3.2 Global Forecasted Revenue of Angiotensin Converting Enzyme (ACE) Inhibitors by Region (2022-2027) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT) Growth Rate Comparison by Type (2021-2027) Table 2. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT) Comparison by Application (2021-2027) Table 3. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Region (US$ Million) (2016 VS 2021 VS 2027) Table 4. Key Manufacturers Angiotensin Converting Enzyme (ACE) Inhibitors Covered in This Study Table 5. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT) of Key Manufacturers (2016-2021) Table 6. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Manufacturers (2016-2021) Table 7. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (US$ Million) by Manufacturers (2016-2021) Table 8. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Manufacturers (2016-2021) Table 9. Global Market Angiotensin Converting Enzyme (ACE) Inhibitors Average Price (USD/Unit) of Key Manufacturers (2016-2021) Table 10. Manufacturers Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Sites and Area Served Table 11. Manufacturers Angiotensin Converting Enzyme (ACE) Inhibitors Product Type Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Angiotensin Converting Enzyme (ACE) Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Angiotensin Converting Enzyme (ACE) Inhibitors as of 2020) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region (2016-2021) & (K MT) Table 16. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Region (2016-2021) Table 17. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region (2016-2021) & (US$ Million) Table 18. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2016-2021) & (K MT) Table 19. North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2016-2021) Table 20. North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2016-2021) & (US$ Million) Table 21. North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country (2016-2021) Table 22. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2016-2021) & (K MT) Table 23. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2016-2021) Table 24. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2016-2021) & (US$ Million) Table 25. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country (2016-2021) Table 26. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region (2016-2021) & (K MT) Table 27. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Region (2016-2021) Table 28. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region (2016-2021) & (US$ Million) Table 29. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Region (2016-2021) Table 30. Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2016-2021) & (K MT) Table 31. Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2016-2021) Table 32. Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2016-2021) & (US$ Million) Table 33. Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country (2016-2021) Table 34. Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2016-2021) & (K MT) Table 35. Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2016-2021) Table 36. Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2016-2021) & (US$ Million) Table 37. Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country (2016-2021) Table 38. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT) by Type (2016-2021) Table 39. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2016-2021) Table 40. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (Million US$) by Type (2016-2021) Table 41. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Type (2016-2021) Table 42. Global Angiotensin Converting Enzyme (ACE) Inhibitors Price (USD/Unit) by Type (2016-2021) Table 43. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT) by Application (2016-2021) Table 44. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2016-2021) Table 45. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue (Million US$) by Application (2016-2021) Table 46. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Application (2016-2021) Table 47. Global Angiotensin Converting Enzyme (ACE) Inhibitors Price (USD/Unit) by Application (2016-2021) Table 48. Abbott Laboratories Corporation Information Table 49. Abbott Laboratories Description and Business Overview Table 50. Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 51. Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Product Table 52. Abbott Laboratories Recent Developments/Updates Table 53. Pfizer Corporation Information Table 54. Pfizer Description and Business Overview Table 55. Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 56. Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Product Table 57. Pfizer Recent Developments/Updates Table 58. Novartis Corporation Information Table 59. Novartis Description and Business Overview Table 60. Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 61. Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Product Table 62. Novartis Recent Developments/Updates Table 63. Merck Corporation Information Table 64. Merck Description and Business Overview Table 65. Merck Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 66. Merck Angiotensin Converting Enzyme (ACE) Inhibitors Product Table 67. Merck Recent Developments/Updates Table 68. Astra Zeneca Corporation Information Table 69. Astra Zeneca Description and Business Overview Table 70. Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 71. Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Product Table 72. Astra Zeneca Recent Developments/Updates Table 73. Jhonson and Johnson Corporation Information Table 74. Jhonson and Johnson Description and Business Overview Table 75. Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 76. Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Product Table 77. Jhonson and Johnson Recent Developments/Updates Table 78. Eli Lilly Corporation Information Table 79. Eli Lilly Description and Business Overview Table 80. Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 81. Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Product Table 82. Eli Lilly Recent Developments/Updates Table 83. Sanofi Corporation Information Table 84. Sanofi Description and Business Overview Table 85. Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 86. Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Product Table 87. Sanofi Recent Developments/Updates Table 88. Bristol-Myers Squibb Corporation Information Table 89. Bristol-Myers Squibb Description and Business Overview Table 90. Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 91. Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Product Table 92. Bristol-Myers Squibb Recent Developments/Updates Table 93. Bayer Corporation Information Table 94. Bayer Description and Business Overview Table 95. Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 96. Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Product Table 97. Bayer Recent Developments/Updates Table 98. GSK Corporation Information Table 99. GSK Description and Business Overview Table 100. GSK Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 101. GSK Angiotensin Converting Enzyme (ACE) Inhibitors Product Table 102. GSK Recent Developments/Updates Table 103. Teva Pharmaceutical Corporation Information Table 104. Teva Pharmaceutical Description and Business Overview Table 105. Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 106. Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Product Table 107. Teva Pharmaceutical Recent Developments/Updates Table 108. Production Base and Market Concentration Rate of Raw Material Table 109. Key Suppliers of Raw Materials Table 110. Angiotensin Converting Enzyme (ACE) Inhibitors Distributors List Table 111. Angiotensin Converting Enzyme (ACE) Inhibitors Customers List Table 112. Angiotensin Converting Enzyme (ACE) Inhibitors Market Trends Table 113. Angiotensin Converting Enzyme (ACE) Inhibitors Growth Drivers Table 114. Angiotensin Converting Enzyme (ACE) Inhibitors Market Challenges Table 115. Angiotensin Converting Enzyme (ACE) Inhibitors Market Restraints Table 116. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Type (2022-2027) & (K MT) Table 117. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share Forecast by Type (2022-2027) Table 118. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Type (2022-2027) & (US$ Million) Table 119. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share Forecast by Type (2022-2027) Table 120. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Application (2022-2027) & (K MT) Table 121. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share Forecast by Application (2022-2027) Table 122. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Application (2022-2027) & (US$ Million) Table 123. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share Forecast by Application (2022-2027) Table 124. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Region (2022-2027) & (K MT) Table 125. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share Forecast by Region (2022-2027) Table 126. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Region (2022-2027) & (US$ Million) Table 127. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share Forecast by Region (2022-2027) Table 128. Research Programs/Design for This Report Table 129. Key Data Information from Secondary Sources Table 130. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Angiotensin Converting Enzyme (ACE) Inhibitors Figure 2. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Share by Type in 2020 & 2027 Figure 3. Sulfhydryl-containing Agents Product Picture Figure 4. Dicarboxylate-containing Agents Product Picture Figure 5. Phosphonate-containing Agents Product Picture Figure 6. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Share by Application in 2020 & 2027 Figure 7. Hypertension Figure 8. Cardiovascular Diseases Figure 9. Kidney Diseases Figure 10. Other Figure 11. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 12. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size 2016-2027 (US$ Million) Figure 13. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales 2016-2027 (K MT) Figure 14. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size Market Share by Region: 2016 VS 20210 VS 2027 Figure 15. Angiotensin Converting Enzyme (ACE) Inhibitors Sales Share by Manufacturers in 2020 Figure 16. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Manufacturers in 2020 Figure 17. The Global 5 and 10 Largest Angiotensin Converting Enzyme (ACE) Inhibitors Players: Market Share by Revenue in 2020 Figure 18. Angiotensin Converting Enzyme (ACE) Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021 Figure 19. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Region (2016-2021) Figure 20. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Region in 2020 Figure 21. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Region (2016-2021) Figure 22. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Region in 2020 Figure 23. U.S. Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 24. Canada Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 25. Germany Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 26. France Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 27. U.K. Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 28. Italy Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 29. Russia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 30. China Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 31. Japan Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 32. South Korea Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 33. India Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 34. Australia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 35. Taiwan Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 36. Indonesia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 37. Thailand Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 38. Malaysia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 39. Philippines Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 40. Vietnam Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 41. Mexico Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 42. Brazil Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 43. Argentina Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 44. Turkey Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 45. Saudi Arabia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 46. U.A.E Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 47. Sales Market Share of Angiotensin Converting Enzyme (ACE) Inhibitors by Type (2016-2021) Figure 48. Sales Market Share of Angiotensin Converting Enzyme (ACE) Inhibitors by Application (2016-2021) Figure 49. Sales Market Share of Angiotensin Converting Enzyme (ACE) Inhibitors by Application in 2020 Figure 50. Revenue Share of Angiotensin Converting Enzyme (ACE) Inhibitors by Application (2016-2021) Figure 51. Revenue Share of Angiotensin Converting Enzyme (ACE) Inhibitors by Application in 2020 Figure 52. Manufacturing Cost Structure of Angiotensin Converting Enzyme (ACE) Inhibitors Figure 53. Manufacturing Process Analysis of Angiotensin Converting Enzyme (ACE) Inhibitors Figure 54. Angiotensin Converting Enzyme (ACE) Inhibitors Industrial Chain Analysis Figure 55. Channels of Distribution Figure 56. Distributors Profiles Figure 57. Bottom-up and Top-down Approaches for This Report Figure 58. Data Triangulation Figure 59. Key Executives Interviewed

Abbott Laboratories Pfizer Novartis Merck Astra Zeneca Jhonson and Johnson Eli Lilly Sanofi Bristol-Myers Squibb Bayer GSK Teva Pharmaceutical